Skip to main content

Orchid Posts Flat Q2 Revenues, Narrowed Loss

NEW YORK, Aug, 7 (GenomeWeb News) - Orchid Biosciences to reported flat revenue in the second quarter amid decreased R&D spending and narrowed net loss.


Total revenue for the period ended June 30 was $12.4 million, unchanged from the year-ago quarter, Orchid said. However, receipts from the company's core business unit of forensic, paternity, and public health DNA testing increased 11 percent year over year.


R&D spending fell to $1 million, from $5 million, and net loss narrowed to $10.2 million, or $.18 per share, from $12.2 million, or $.22 per share, in the second quarter 2002.


Orchid said it had roughly $15.7 million in cash and cash equivalents as of June 30.


Click here for more information.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.